Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tianli Fan has a total of 81 co-authors. Here are the top co-authors by number of shared publications:

  • Na Gao

    The Fifth Clinical Medical College of Henan University of Chinese Medicine (Zhengzhou People's Hospital), Zhengzhou, 450003, Henan, P.R. China

    11 shared publications
  • Zhenzhen Yang

    The Fifth Clinical Medical College of Henan University of Chinese Medicine (Zhengzhou People’s Hospital), Zhengzhou, P.R. China

    10 shared publications
  • Jing Li

    Zhengzhou Univ, Sch Basic Med, Dept Pharmacol, Zhengzhou 450001, Henan, Peoples R China

    5 shared publications
  • Pan Gao

    The Fifth Clinical Medical College of Henan University of Chinese Medicine (Zhengzhou People's Hospital), Zhengzhou, 450003, Henan, P.R. China

    5 shared publications
  • Yinsen Song

    The Fifth Clinical Medical College of Henan University of Chinese Medicine (Zhengzhou People’s Hospital), Zhengzhou, People’s Republic of China

    5 shared publications
  • Zhengfan Gao

    Zhengzhou Univ, Sch Basic Med, Dept Pharmacol, Zhengzhou 450001, Henan, Peoples R China

    5 shared publications

Latest Publications

  • The Natural Flavonoid Pectolinarigenin Targets On‐Canonical NF‐κB Pathway to Inhibit Esophageal Squamous Cell Carcinoma and Enhances Paclitaxel Efficacy

    by Erling Li, Lipeng Wang, Wenxu Hu, Menglin Zhu, Zixuan Shi, Peirong Xu, Tianli Fan, Guiqin Hou

    Pectolinarigenin (PEC) is a natural flavonoid compound derived from Chinese herbal medicines. Previous studies have demonstrated its significant inhibitory effects against various malignancies. However, the effect and molecular mechanism of PEC in esophageal squamous cell carcinoma (ESCC) as well as its potential for combination with clinical chemotherapeutics for ESCC treatment is still obscure. Here, we systematically explored the anti‐ESCC effects of PEC, elucidated its molecular mechanism, and evaluated its synergistic therapeutic potential with paclitaxel (PTX), a first‐line chemotherapeutic agent for ESCC. The results showed that PEC obviously restrained proliferation and migration, and induced apoptosis of ESCC cells. Mechanistically, we found that PEC targets the non‐canonical pathway of NF‐κB, specifically preventing nuclear translocation of p52 and RELB, thus suppressing the transcriptional activity of this pathway. Moreover, we confirmed that PEC markedly inhibited tumor growth and exhibited a strong synergistic effect on the progression of ESCC when combined with PTX using a xenograft model of nude mice. Our research results have revealed a new molecular mechanism for the anti‐ESCC efficiency of PEC. This study highlights PEC potential as a promising candidate for ESCC monotherapy or combination therapy with PTX and points out a new strategy for the clinical treatment of natural flavonoids to ESCC.


  • Open Access

    Application of targeted next-generation sequencing in bronchoalveolar lavage fluid testing for pathogen identification in pulmonary infections

    by Zhenzhen Yang, Cheng Chang, Xiaolin Zhang, Ruiting Feng, Chen Wang, Jingjie Meng, Lu Zhang, Yinsen Song, Tianli Fan

  • Open Access

    Identification of replication factor C subunit 4 as a potential therapeutic target in esophageal squamous cell carcinoma based on bioinformatic analysis and machine learning

    by Zhenzhen Yang, Cheng Chang, Na Gao, Pan Gao, Ruiting Feng, Jingjie Meng, Xianhui Yang, Yinsen Song, Tianli Fan

    Esophageal squamous cell carcinoma (ESCC) is one of the highly lethal and aggressive malignant tumors worldwide. To effectively prevent and treat this disease, the search for novel molecular targets is of great significance for promoting the molecular diagnosis and targeted therapy of ESCC. Gene expression profiles from gene expression omnibus (GEO) datasets were normalized and analyzed to identify differentially expressed genes. Functional enrichment, protein-protein interaction network, and machine learning algorithms were applied for biomarker screening. Immune infiltration analysis and immunohistochemistry were performed to assess clinical relevance. Analysis identified 752 differentially expressed genes in ESCC, with enrichment in upregulated pathways including DNA replication and mismatch repair, and downregulated pathways such as autophagy. Gene Ontology/Kyoto Encyclopedia of Genes and Genomes analyses revealed complex molecular networks driving ESCC. Key hub genes and diagnostic biomarkers aurora kinase A (AURKA), kinesin family member 4 A (KIF4A), and replication factor C subunit 4 (RFC4) were identified, with high diagnostic area under the receiver operating characteristic curve values from 0.976 to 0.983. RFC4 expression correlated with mast cell infiltration patterns, showed elevated expression in ESCC tissues via immunohistochemistry, and was associated with poor prognosis. This study identifies AURKA, KIF4A, and RFC4 as potential in silico biomarkers for ESCC. This study further highlights RFC4 as a promising candidate for diagnostic and prognostic applications, offering new insights into prevention strategies for ESCC.

  • Open Access

    Global Burden and 2050 Projections of Colorectal Cancer Attributable to Dietary Risk Factors: Insights From the GBD 2021 Study

    by Haozhe Zhang, Linlin Guo, Qiongzhe Sun, Na Gao, Zhenzhen Yang, Zhu Wu, Ren Niu, Tianli Fan

    Background: Colorectal cancer (CRC) remains a major cause of cancer‐related mortality worldwide. Diet is among the few modifiable determinants of CRC risk, yet the global contribution of specific dietary factors over time, and their projected impact, is not fully understood. Assessing both historical patterns and future trends is essential for guiding prevention strategies. Methods: We used estimates from the Global Burden of Disease (GBD) 2021 study to quantify CRC mortality, disability‐adjusted life years (DALYs), and age‐standardized rates (ASRs) attributable to six dietary risk factors across 204 countries and territories from 1990 to 2021. Analyses were stratified by sex, age, sociodemographic index (SDI), and region. We applied decomposition analysis to separate demographic from epidemiological drivers and a Bayesian age–period–cohort (BAPC) model to project ASRs through 2050. Results: Between 1990 and 2021, global ASRs for diet‐related CRC declined, yet the absolute number of cases rose. In 2021, low whole grain intake (28.38%), low milk intake (24.01%), and high red meat consumption (23.31%) were the leading dietary risks for CRC mortality, with comparable rankings for DALYs. Men, older adults, and high‐SDI populations experienced the heaviest burden, while the highest ASRs linked to low calcium intake occurred in low‐SDI regions, particularly in Southeast Asia, Africa, the Caribbean, and Oceania. Modelled projections suggest continued global declines in ASRs through 2050, but with slower reductions in high‐SDI settings and relatively larger gains in some low‐ and middle‐SDI regions; disparities are unlikely to close. Conclusion: Although diet‐attributable CRC rates have declined, the global burden remains substantial and heterogeneous across SDI strata. Projections to 2050 indicate the need for SDI‐tailored prevention strategies, prioritizing reductions in red and processed meat in high‐SDI settings and improvements in calcium‐related intake in low‐SDI regions, supported by context‐appropriate dietary guidelines and public health programmes.


  • Open Access

    Integrating network pharmacology and molecular modeling to decipher the anti-esophageal squamous cell carcinoma mechanisms of Bidens pilosa L

    by Zhenzhen Yang, Cheng Chang, Na Gao, Pan Gao, Yinsen Song, Ruiting Feng, Jingjie Meng, Chen Wang, Haozhe Zhang, Tianli Fan

    Bidens pilosa L (BL), known for its anti-inflammatory, antioxidant, and anticancer properties across multiple malignancies, was investigated for its potential therapeutic effects against esophageal squamous cell carcinoma (ESCC). Through integrative network pharmacology and computational approaches, 10 bioactive compounds from BL were identified from HERB 2.0, symMap, BATMAN-TCM (target prediction score cutoff = 20, adjusted P-value = 0.05 for target analyses), TCMSP (oral bioavailability ≥ 30% and drug likeness ≥ 0.18), and ETCM 2.0 databases, while 3,993 ESCC-associated targets were retrieved from OMIM, GeneCards, and DisGeNET. Cross-analysis revealed 214 shared targets, with tyrosine-protein kinase, epidermal growth factor receptor, and alpha serine/threonine-protein kinase emerging as central hubs in protein-protein interaction networks. Functional enrichment analysis highlighted significant involvement in cellular responses to hormone stimuli, nitrogen compounds, and phosphorylation, with key pathways including cancer, PI3K-Akt, and Ras signaling. Molecular docking demonstrated high-affinity binding of (2E)-2-(3,4-Dihydroxybenzylidene)-6,7-Dihydroxy-Benzofuran-3-One (− 10.4 kcal/mol), Luteolin (− 10.1 kcal/mol), and Okanin (− 9.7 kcal/mol) to matrix metalloproteinase-9 (MMP9), specifically targeting catalytic residues GLU227 and TYR245. Quantum chemical calculations further revealed narrow HOMO-LUMO gaps for Luteolin (ΔE = 2.41 eV) and Okanin (ΔE = 2.93 eV), indicating high reactivity, while molecular dynamics simulations confirmed stable MMP9-ligand complexes (nearly − 200 kJ/mol), with Okanin exhibiting faster equilibration than Luteolin. The analysis of datasets from TCGA and GEO revealed that MMP9 is significantly upregulated in esophageal squamous cell carcinoma tissues compared to normal esophageal tissues. Meanwhile, Luteolin significantly inhibited the proliferation, migration, invasion and epithelial-mesenchymal transition (EMT) capabilities of ESCC in vitro experiments.These findings collectively suggest that BL exerts anti-ESCC effects in silico through multi-target synergy, with Luteolin and Okanin identified as promising MMP9 inhibitors, providing a mechanistic foundation for future drug development.


  • Open Access

    Luteolin enhances drug chemosensitivity by downregulating the FAK/PI3K/AKT pathway in paclitaxel‑resistant esophageal squamous cell carcinoma

    by Zhenzhen Yang, Hongtao Liu, Yinsen Song, Na Gao, Pan Gao, Yiran Hui, Yueheng Li, Tianli Fan

    Drug resistance is a key factor underlying the failure of tumor chemotherapy. It enhances the stem‑like cell properties of cancer cells, tumor metastasis and relapse. Luteolin is a natural flavonoid with strong anti‑tumor effects. However, the mechanism(s) by which luteolin protects against paclitaxel (PTX)‑resistant cancer cell remains to be elucidated. The inhibitory effect of luteolin on the proliferation of EC1/PTX and EC1 cells was detected by cell counting kit‑8 assay. Colony formation and flow cytometry assays were used to assess clonogenic capacity, cell cycle and apoptosis. Wound healing and Transwell invasion tests were used to investigate the effects of luteolin on the migration and invasion of EC1/PTX cells. Western blotting was used to detect the protein levels of EMT‑related proteins and stem cell markers after sphere formation. Parental cells and drug‑resistant cells were screened by high‑throughput sequencing to detect the differential expression of RNA and differential genes. ELISA and western blotting were used to verify the screened PI3K/Akt signaling pathway, key proteins of which were explored by molecular docking. Hematoxylin and eosin staining and TUNEL staining were used to observe tumor xenografts on morphology and apoptosis in nude mice. The present study found that luteolin inhibited tumor resistance (inhibited proliferation, induced cell cycle arrest and apoptosis and hindered migration invasion, EMT and stem cell spherification) in vitro in PTX‑resistant esophageal squamous cell carcinoma (ESCC) cells. In addition, luteolin enhanced drug sensitivity and promoted the apoptosis of drug‑resistant ESCC cells in combination with PTX. Mechanistically, luteolin may inhibit the PI3K/AKT signaling pathway by binding to the active sites of focal adhesion kinase (FAK), Src and AKT. Notably, luteolin lowered the tumorigenic potential of PTX‑resistant ESCC cells but did not show significant toxicity in vivo. Luteolin enhanced drug chemosensitivity by downregulating the FAK/PI3K/AKT pathway in PTX‑resistant ESCC and could be a promising agent for the treatment of PTX‑resistant ESCC cancers.


  • Open Access

    Unveiling the mechanism of Buddleja officinalis against esophageal squamous cell carcinoma through network pharmacology and molecular docking approaches

    by Cheng Chang, Zhen Zhen Yang, Yin Sen Song, Na Gao, Hao Zhe Zhang, Xiao Lin Zhang, Tian Li Fan

    In this research, we aim to explore the underlying mechanism of Buddleja officinalis (BO) in inhibiting esophageal squamous cell carcinoma (ESCC) by means of network pharmacology and molecular docking approaches. First, BO component targets were determined from the Traditional Chinese Medicine Systematic Pharmacology and HERB databases (known as BenCaoZuJian in Chinese transliteration), and ESCC disease targets were identified from GeneCards and DisGeNET databases. Second, the Venny 2.1 online tool was utilized to visualize the intersection targets, and shared potential targets between BO and ESCC were identified using the STRING database. Third, the component-target-pathway networks were constructed using Cytoscape software. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes were utilized for further analyzing the mechanism of BO in inhibiting ESCC. Finally, molecular docking technique was employed to delineate the docking profiles of BO and determine the optimal active component, which is threonine protein kinase (AKT1). We screened six active components and 227 targets from BO, of which 24 were shared targets of ESCC and BO. The network pharmacology analysis indicated core targets with high degrees, namely, serum albumin, insulin-like growth factor 1 receptor, AKT1, estrogen receptor, and basic fibroblast growth factor receptor 1, which are the most likely binding sites for the active components in BO. The related signaling pathways underpinning the inhibition of ESCC by BO encompass MAPK signaling pathway, adhesion junction pathway, and gastric cancer pathway. Moreover, linarin was recognized as the most suitable component for AKT1. Our results revealed that BO exhibits multicomponent, multi-target, and multi-pathway characteristics, which offer a scientific foundation for elucidating its therapeutic mechanism in ESCC and present novel insights for future investigations.


  • Open Access

    Comprehensive Molecular Analyses of Notch Pathway-Related Genes to Predict Prognosis and Immunotherapy Response in Patients with Gastric Cancer

    by Yinsen Song, Na Gao, Zhenzhen Yang, Sisen Zhang, Tianli Fan, Baojun Zhang

    Gastric cancer (GC) is a highly molecular heterogeneous tumor with unfavorable outcomes. The Notch signaling pathway is an important regulator of immune cell differentiation and has been associated with autoimmune disorders, the development of tumors, and immunomodulation caused by tumors. In this study, by developing a gene signature based on genes relevant to the Notch pathway, we could improve our ability to predict the outcome of patients with GC. From the TCGA database, RNA sequencing data of GC tumors and associated normal tissues were obtained. Microarray data were collected from GEO datasets. The Molecular Signature Database (MSigDB) was accessed in order to retrieve sets of human Notch pathway-related genes (NPRGs). The LASSO analysis performed on the TCGA cohort was used to generate a multigene signature based on prognostic NPRGs. In order to validate the gene signature, the GEO cohort was utilized. Using the CIBERSORT method, we were able to determine the amounts of immune cell infiltration in the GC. In this study, a total of 21 differentially expressed NPRGs were obtained between GC specimens and nontumor specimens. The construction of a prognostic prediction model for patients with GC involved the identification and selection of three different NPRGs. According to the appropriate cutoff value, the patients with GC were divided into two groups: those with a low risk and those with a high risk. The time-dependent ROC curves demonstrated that the new model had satisfactory performance when it came to prognostic prediction. Multivariate assays confirmed that the risk score was an independent marker that may be used to predict the outcome of GC. In addition, the generated nomogram demonstrated a high level of predictive usefulness. Moreover, the scores of immunological infiltration of the majority of immune cells were distinctly different between the two groups, and the low-risk group responded to immunotherapy in a significantly greater degree. According to the results of a functional enrichment study of candidate genes, there are multiple pathways and processes associated with cancer. Taken together, a new gene model associated with the Notch pathway may be utilized for the purpose of predicting the prognosis of GC. One potential method of treatment for GC is to focus on NPRGs.


    • 1 January 2023
      • Vol. 15  (4) , 2426-2442

    Long non-coding RNA LINC00707, a prognostic marker, regulates cell proliferation, apoptosis, and EMT in esophageal squamous cell carcinoma

    by Na Gao, Guozhong Jiang, Zhengfan Gao, Mengfei Cui, Jing Li, Hongtao Liu, Tianli Fan

    Background: Long intergenic non-protein coding RNA 707 (LINC00707) has been identified as a cancer -associated long non-coding RNA (lncRNA) in a variety of cancers. However, the functions and molecular mecha-nisms of LINC00707 in esophageal squamous cell carcinoma (ESCC) are still unclear. Methods: The expression of LINC00707 in esophageal cancer (ESCA) and ESCC tissues was determined by online tools, RNA-sequence (RNA-seq) dataset, and quantitative real time polymerase chain reaction (qRT-PCR). The associations between LINC00707 expression and clinicopathologic features and prognosis were investigated. Furthermore, the expression of LINC00707 in ESCC cell lines was determined by qRT-PCR. Then, using LncACTdb 2.0 database, combined with loss-of-function assay verification, we investigated the biologic role of LINC00707 in ESCC cell growth, apoptosis, invasion, and migration by CCK-8, colony formation, flow cytometry and transwell assays. Finally, western blot was used to evaluate the regulatory effect of LINC00707 on PI3K/Akt signaling pathway. Results: Increased LINC00707 expression was exhibited in ESCC tissues and cell lines. High expression of LINC00707 was positively associated with higher tumor-node-metastasis (TNM) stage and lymph node metastasis. Furthermore, LINC00707 expression was significantly higher in patients who drink alcohol, have lymph node metastasis, and harbor higher tumor stage. In addition, Kaplan-Meier survival analysis and receiver operating characteristic (ROC) curve confirmed the feasibil-ity of LINC00707 as a prognostic signature or diagnostic marker. Functional experiments showed that LINC00707 downregulation suppressed ESCC cell proliferation, and metastasis, and induced ESCC cell apoptosis. Mechanistic investigation demonstrated that LINC00707 activated the PI3K/Akt signaling pathway in ESCC cells. Conclusions: Our findings suggest LINC00707 functions as an oncogenic lncRNA in ESCC, and imply that LINC00707 may be a promising prognostic biomarker and therapeutic target for ESCC patients.


    • 1 January 2023
      • Vol. 15  (3) , 2109-2121

    Characteristics, polarization and targeted therapy of mononuclear macrophages in rheumatoid arthritis

    by Yinsen Song, Na Gao, Zhenzhen Yang, Lu Zhang, Yijia Wang, Sisen Zhang, Tianli Fan

    Macrophages are the core of the pathophysiology of rheumatoid arthritis (RA). They participate in specific and non-specific immunological responses, have phagocytosis, chemotaxis and immune regulatory functions, and are involved in the onset and progression of RA. In recent years, research on the pathophysiology of RA has focused on the polarization and functions of classically activated M1 and selectively activated M2 macrophage subtypes. M1 macrophages release different proinflammatory cytokines, thus driving the chronic proinflammatory, tissue destruction and pain response in RA. M2 macrophages play an anti-inflammatory role. Because of the important role of monocyte-macrophage in RA, drug research targeting monocyte-macrophage can bring us more hope for treatment of RA. This study reviewed the characteristics, plasticity, molecular activation mechanism and relationship of RA with mononuclear macrophages, as well as the transformative potential of macrophages in developing new therapeutic drugs for clinical practice.